At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 140 enrolled
Drug / intervention
Tralokinumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid Use in Adults and Adolescents With Oral Corticosteroid Dependent Asthma (TROPOS)
In Brief
A Phase 3 clinical trial evaluating Tralokinumab and Placebo for Asthma. Completed, enrolled 140 participants across 51 sites in 7 countries.
Detailed Summary
A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid dependent Asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesBelgium, France, Germany, Netherlands, Poland, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartFeb 2015
Primary CompletionSep 2017
TodayJul 2026
First PostedNov 3, 2014
Enrollment StartFeb 19, 2015
Primary CompletionSep 7, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.7 years ago
Interventions
Tralokinumabbiological
Tralokinumab dose
Placeboother
Placebo dose